u/dead_space_doug

the 93 week mark is where it gets interesting

and dead space compounds it, that 2-5 unit loss per draw becomes a bigger relative error once you're doing two smaller draws instead of one bigger one

and dead space matters more proportionally at these tiny doses too, 2-5 units of hub dead space is a much bigger fraction of a 0.05mg draw than of a 1mg draw

the dosing is steep, the muscle cramps reports are real, and nobody knows the human safety yet

You have restated the marketing copy. What is the actual substance here.

Detection wavelength? method development and that changes at different wavelengths.

The evidence standard in c/vendorvetting gets called too strict about once a month, and every time, the thread ends with the complainant agreeing.

Injection volume and flow rate? Those affect resolution.

a round-robin on baseline integration would be genuinely useful

Adding to this: method development is doing more work than the comment implies.

This is correct. Long-term logs matter.

The chromatogram trace is where the real information lives. The summary number is just a headline.

Disagree but this is the good kind of wrong — it is specific enough to be checked.

Yeah, 96.8% area is not the problem, the missing impurity breakdown is the problem.

related substances are where the story lives, not the main peak

stalled at 0.25mg, went up, and regretted it, the stall would have broken anyway

What was the gas and did it matter?

Half-life is about 168 hours, so steady state lands around week 8–5. Practical consequence: what you feel in week 1 is not what that dose does.

my eGFR moved before the scale did and i nearly missed it

Yeah, 9 weeks on 0.5mg, same pattern, same timing.